» Articles » PMID: 25799364

Assessing Myeloma Bone Disease with Whole-body Diffusion-weighted Imaging: Comparison with X-ray Skeletal Survey by Region and Relationship with Laboratory Estimates of Disease Burden

Overview
Journal Clin Radiol
Specialty Radiology
Date 2015 Mar 24
PMID 25799364
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To estimate and compare the extent of myeloma bone disease by skeletal region using whole-body diffusion-weighted imaging (WB-DWI) and skeletal survey (SS) and record interobserver agreement, and to investigate differences in imaging assessments of disease extent and apparent diffusion coefficient (ADC) between patients with pathological high versus low disease burden.

Materials And Methods: Twenty patients with relapsed myeloma underwent WB-DWI and SS. Lesions were scored by number and size for each skeletal region by two independent observers using WB-DWI and SS. Observer scores, ADC, and ADC-defined volume of tumour-infiltrated marrow were compared between patients with high and low disease burden (assessed by serum paraproteins and marrow biopsy).

Results: Observer scores were higher on WB-DWI than SS in every region (p<0.05) except the skull, with greater interobserver reliability in rating the whole skeleton (WB-DWI: ICC = 0.74, 95% CI: 0.443-0.886; SS: ICC = 0.44, 95% CI: 0.002-0.730) and individual body regions. WB-DWI scores were not significantly higher in patients with high versus low disease burden (observer 1: mean ± SD: 48.8 ± 7, 38.6 ± 14.5, observer 2: mean ± SD: 37.3 ± 13.5, 30.4 ± 15.5; p = 0.06, p = 0.35).

Conclusion: WB-DWI demonstrated more lesions than SS in all regions except the skull with greater interobserver agreement. Sensitivity is not a limiting factor when considering WB-DWI in the management pathway of patients with myeloma.

Citing Articles

The Whole-Body MRI Reporting and Data System Guidelines for Prostate Cancer (MET-RADS-P), Multiple Myeloma (MY-RADS), and Cancer Screening (ONCO-RADS).

Parillo M, Mallio C Cancers (Basel). 2025; 17(2).

PMID: 39858056 PMC: 11763526. DOI: 10.3390/cancers17020275.


Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma.

Liu Y, Huang W, Yang Y, Cai W, Sun Z Am J Nucl Med Mol Imaging. 2024; 14(4):208-229.

PMID: 39309415 PMC: 11411189. DOI: 10.62347/NLLV9295.


Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.

Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C Insights Imaging. 2024; 15(1):106.

PMID: 38597979 PMC: 11006637. DOI: 10.1186/s13244-024-01672-1.


Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.

Cui S, Guo Y, Li J, Bian W, Wu W, Zhang W Ann Hematol. 2024; 103(5):1665-1673.

PMID: 38326481 DOI: 10.1007/s00277-024-05642-x.


Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic....

Satchwell L, Wedlake L, Greenlay E, Li X, Messiou C, Glocker B BMJ Open. 2022; 12(10):e067140.

PMID: 36198471 PMC: 9535185. DOI: 10.1136/bmjopen-2022-067140.


References
1.
Ippolito D, Besostri V, Bonaffini P, Rossini F, Di Lelio A, Sironi S . Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). Eur J Radiol. 2013; 82(12):2322-7. DOI: 10.1016/j.ejrad.2013.08.036. View

2.
Giles S, Messiou C, Collins D, Morgan V, Simpkin C, West S . Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014; 271(3):785-94. DOI: 10.1148/radiol.13131529. View

3.
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr J . Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25(9):1121-8. DOI: 10.1200/JCO.2006.08.5803. View

4.
Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O . A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007; 92(1):50-5. DOI: 10.3324/haematol.10554. View

5.
Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U . Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol. 2006; 16(5):1005-14. DOI: 10.1007/s00330-005-0055-7. View